(NASDAQ: MLTX) Moonlake Immunotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.62%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.53%.
Moonlake Immunotherapeutics's earnings in 2026 is -$230,321,000.On average, 17 Wall Street analysts forecast MLTX's earnings for 2026 to be -$267,917,959, with the lowest MLTX earnings forecast at -$303,523,676, and the highest MLTX earnings forecast at -$200,335,955. On average, 16 Wall Street analysts forecast MLTX's earnings for 2027 to be -$265,923,924, with the lowest MLTX earnings forecast at -$365,948,445, and the highest MLTX earnings forecast at -$195,817,099.
In 2028, MLTX is forecast to generate -$189,375,936 in earnings, with the lowest earnings forecast at -$340,427,668 and the highest earnings forecast at -$65,523,414.